August 2026 Research Update

This month added more real-world information on how different first treatments for Waldenstrom macroglobulinemia have performed outside of clinical trials. Across these studies, rituximab-based combinations tended to keep the disease controlled longer, while BTK inhibitors (a targeted pill treatment class) appeared active but were assessed in smaller groups or with limited safety detail. [1] [2]

In a Korean cohort comparing several frontline approaches, rituximab-based regimens had longer time before the disease worsened than other groups, and bendamustine-rituximab stood out within that category for longer disease control than rituximab plus cyclophosphamide-based regimens. Another group of treatments (proteasome inhibitor or IMiD-based regimens) produced the quickest early responses, but disease control was shorter in that dataset. [1]

A smaller single-center study also compared BTK inhibitor-containing therapy with non-BTK inhibitor regimens and reported a higher response rate in the BTK inhibitor group. The same study found that a higher beta-2 microglobulin level at diagnosis was linked with shorter survival and shorter time without progression, suggesting it may act as a general risk marker in that patient group. [2]

These real-world datasets also described what happened when treatment needed to change. In the Korean cohort, over half of patients received a second-line treatment, and the authors reported that the type of first treatment did not reduce BTK inhibitor effectiveness later on, although frontline BTK inhibitor use itself was rare in that cohort. [1]

For patients, this set of studies mainly adds context about what has been happening in routine practice: some rituximab-based combinations were linked with longer periods of disease control, while some other regimens acted faster but did not last as long in the reported cohorts. The BTK inhibitor results are encouraging but are harder to compare directly because the groups were small or the information (like side effects) was not fully captured. This is the kind of evidence that can help explain why different patients may have different treatment journeys, but it does not settle which option is best for any one person. [1] [2]

These studies also highlight that lab and risk markers may matter for understanding prognosis. In one cohort, higher beta-2 microglobulin at diagnosis was linked to worse outcomes, but this was based on a small group and may not apply the same way across all settings. The remaining uncertainty is how well these patterns hold across countries, time periods, and different mixes of patients and treatments. [2] [1]

This month included two large studies focused on what can happen over time or during severe illness in people with Waldenstrom macroglobulinemia. One study described outcomes for patients sick enough to need intensive care, and another tracked second primary cancers over years of follow-up. Together, they give a clearer picture of where the biggest medical risks may cluster: severe infections and organ stress in critical illness, while second cancers overall were not clearly increased, with a borderline signal for certain blood cancers. [3] [4]

Among 151 people with Waldenstrom macroglobulinemia admitted to French ICUs, the most common reason for admission was acute breathing failure, and infections were a leading cause of death. ICU mortality was reported as 20%, and one-year mortality was 40%, showing that an ICU admission often marks a very serious period of illness. The analysis found that more severe organ dysfunction (a higher SOFA score) and autoimmune hemolytic anemia were linked to higher ICU death risk, while hyperviscosity syndrome showed an inverse association in this dataset. [3]

In a Danish population-based cohort of 521 people with LPL/WM, 68 developed a second primary cancer over follow-up, with a cumulative incidence of 9.3% at 5 years and 14.6% at 10 years. Compared with regional cancer rates, overall cancer risk was not clearly increased, but the authors noted a borderline excess in blood cancers driven by myelodysplastic syndrome. The study did not identify clear patient or disease factors that predicted who would develop a second cancer. [4]

For patients and caregivers, these studies mainly add perspective about risks that may come up in certain situations rather than day-to-day expectations. The ICU study helps clarify that when people with Waldenstrom macroglobulinemia become critically ill, infections and organ strain are common issues, and outcomes can be serious in that setting. The second-cancer study suggests that, on average, the overall extra risk compared with the general population was small in that region, but some myeloid blood cancers were seen more than expected. [3] [4]

What remains uncertain is how much these numbers vary across countries, treatment eras, and patient characteristics, and whether the same second-cancer patterns would appear in other populations. Even with uncertainty, these data help many people place rare but important risks into a clearer frame: critical illness episodes can be defining events, and long-term follow-up research continues to watch for second cancers. [3] [4]

This month, case reports highlighted that Waldenstrom macroglobulinemia can sometimes be discovered because something looks "off" in a surprising place, like routine lab results or unexplained fluid around the lungs. The shared message is not that these are common, but that IgM proteins can create confusing signals that require careful confirmation before conclusions are drawn. [5] [6]

In one report, very different sodium and calcium results appeared depending on the lab analyzer platform, and follow-up testing suggested the IgM paraprotein was interfering with the measurements rather than reflecting true electrolyte problems. Dilution, a protein-removal step (PEG precipitation), and direct measurement helped show the abnormal values were largely an artifact, and the workup ultimately led to a diagnosis of Waldenstrom macroglobulinemia. This case matters because it illustrates how paraproteins can distort certain lab tests and why confirmation testing can change the interpretation. [5]

A second report described a person with Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma who developed shortness of breath and pleural effusions (fluid around the lungs) due to IgM-lambda AL amyloidosis. Amyloid was detected in a pleural fluid sample and confirmed by lymph node biopsy, and a change in therapy was followed by reduced fluid and a year without needing drainage. This case adds a practical example of how amyloidosis can be identified from fluid testing and how it can drive symptoms in WM-related disease. [6]

For patients, these reports mainly add awareness about diagnostic complexity rather than providing general expectations. They show that IgM proteins can sometimes interfere with common lab tests, and that WM can sometimes be linked with amyloidosis that causes fluid buildup and breathing symptoms. Because each report describes a single person, the findings may not apply broadly, but they can help explain why extra confirmatory testing is sometimes needed when results do not fit the clinical picture. [5] [6]

What remains uncertain is how often these situations happen and which patients are most at risk, since case reports cannot estimate frequency. Even so, they help clarify the kinds of problems WM-related proteins can cause: confusing laboratory readings in one situation and organ-related symptoms from amyloid deposits in another. This information may matter most when someone has unexpected lab results or unexplained pleural effusions and the care team is trying to pin down the cause. [5] [6]